Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$0.37 - $1.04 $249 - $699
-673 Reduced 0.15%
455,688 $182,000
Q2 2023

Aug 11, 2023

SELL
$0.74 - $1.1 $82,790 - $123,066
-111,879 Reduced 19.69%
456,361 $433,000
Q1 2023

May 12, 2023

BUY
$0.76 - $1.78 $2,745 - $6,429
3,612 Added 0.64%
568,240 $517,000
Q4 2022

Feb 13, 2023

BUY
$1.0 - $58.8 $1,640 - $96,432
1,640 Added 0.29%
564,628 $818,000
Q3 2022

Nov 14, 2022

SELL
$1.32 - $58.0 $19,536 - $858,400
-14,800 Reduced 2.56%
562,988 $795,000
Q2 2022

Aug 12, 2022

SELL
$1.28 - $2.31 $5,242 - $9,461
-4,096 Reduced 0.7%
577,788 $803,000
Q1 2022

May 12, 2022

BUY
$1.82 - $3.5 $5,472 - $10,524
3,007 Added 0.52%
581,884 $1.32 Million
Q4 2021

Feb 10, 2022

BUY
$1.21 - $2.7 $47,592 - $106,199
39,333 Added 7.29%
578,877 $758,000
Q3 2021

Nov 09, 2021

SELL
$2.59 - $3.36 $23,364 - $30,310
-9,021 Reduced 1.64%
539,544 $1.45 Million
Q2 2021

Aug 11, 2021

BUY
$3.11 - $4.87 $1.71 Million - $2.67 Million
548,565 New
548,565 $1.84 Million

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $112M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.